Table 6.6i
Immunosuppression Use for Antirejection Treatment from Transplant to One Year Following Transplantation, 1995 to 2004
Recipients with Pancreas Transplant Alone (PTA) Transplants

	Year of Transplant									
	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Transplants	42	52	79	89	139	134	167	180	158	183
Tx with Antirejection Treatments	24	21	22	21	30	28	20	36	29	34
Antibodies										
Any in Category	54.2%	57.1%	68.2%	52.4%	90.0%	92.9%	65.0%	63.9%	79.3%	58.8%
ALG	4.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	4.2%	42.9%	18.2%	9.5%	0.0%	0.0%	5.0%	0.0%	0.0%	2.9%
OKT3	50.0%	42.9%	59.1%	47.6%	73.3%	57.1%	30.0%	41.7%	27.6%	20.6%
Thymoglobulin	0.0%	0.0%	0.0%	9.5%	40.0%	57.1%	40.0%	33.3%	58.6%	29.4%
Zenapax	0.0%	0.0%	0.0%	0.0%	13.3%	3.6%	5.0%	2.8%	10.3%	2.9%
Simulect	0.0%	0.0%	0.0%	0.0%	3.3%	3.6%	5.0%	0.0%	0.0%	0.0%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	11.1%	37.9%	26.5%
Corticosteroids										
Any in Category	50.0%	90.5%	63.6%	71.4%	73.3%	78.6%	90.0%	83.3%	79.3%	85.3%
Steroids	50.0%	90.5%	63.6%	71.4%	73.3%	78.6%	90.0%	83.3%	79.3%	85.3%
Antimetabolites										
Any in Category	0.0%	0.0%	4.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	0.0%	0.0%	4.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.